All posts by U.S. Stem Cell, Inc

USRM Demonstrates 99% Reduction in Severity of Psoriasis Utilizing Stem Cells

Autoimmune Skin Condition Affects More Than 7 million in the United States

___________________________________________

SUNRISE, FL – March 21, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has published in the scientific literature that it has successfully demonstrated a 99 percent reduction in-human of the severity of psoriasis using a patient’s autologous stem cells.

The scientific paper, which is authored by USRM Chief Science Officer Dr. Kristin Comella and her USRM colleagues, is published in the International Medical Case Reports Journal, 2018:11 59-64.  

To the best of USRM management’s knowledge, this is the first result in the world published using stromal vascular fraction (SVF) and autologous stem cells in the successful treatment of psoriasis.

“This is a breakthrough for the more than 7 million Americans suffering from psoriasis, and is another example of how a patient’s own stem cells offer healing modalities for autoimmune conditions,” said Dr. Comella.  “Although we require additional studies to further develop more extensive protocol in treating patients with this condition, this is a benchmark indicating there is significant reason to believe the use of autologous stem cells is beneficial in combating this disease.”

Stromal vascular fraction (SVF) is a mixture of adipose-derived stem cells/mesenchymal stem cells, endothelial/progenitors, pericytes, fibroblasts, and other cells) obtained from a patient’s own fat tissue. Approximately 60 mL was collected under local anesthesia via a mini-lipoaspirate procedure, which was then separated from the adipocytes via centrifugation after utilizing USRM’s AdipocellTM kit to apply enzymatic digestion.

The cells were then resuspended in normal saline and injected via intravenous bolus push. The subject was monitored over a period of 12 months, and demonstrated no safety or adverse events.  The subject demonstrated a significant (99%) decrease in symptoms with a noticeable difference in skin quality appearance. Psoriasis area and severity index score went from 50.4 at baseline to 0.3 at 1 month follow-up.

Overall, the subject reported improved quality of life and willingness to continue treatments. This successful initial case study demonstrates that this may be a feasible treatment plan for patients suffering from psoriasis.

In this scientific paper, Dr. Comella et al. describe the rationale and, to their knowledge, the first clinical implementation of SVF intravenously in a patient with severe psoriasis.

“We are so proud of the work Dr. Comella and our team are doing to forge novel applications of autologous stem cells to treat a whole host of autoimmune issues,” said Mike Tomas, USRM’s Chief Executive Officer.  “What better fit for a patient than their own stem cells as a healing treatment. We look forward to continued investigation of this and other conditions to treat with autologous stem cells.”

Psoriasis is an autoimmune disease affecting 2 percent of the population worldwide and approximately 7.5 million people in the United States1. Psoriasis patients present with erythematous scaly well-defined plaques, with the scalp, knees, elbows, hands, and feet being the most commonly affected areas.2 Approximately 20% of psoriasis patients present with moderate to severe psoriasis, with more than 5% of the body surface affected. Fifteen percent of patients with psoriasis will develop psoriatic arthritis, occasionally with joint complaints such as dactylitis, sacroiliitis, enthesopathy, and spondylitis, occurring before cutaneous psoriasis. This condition can cause joint destruction due to the chronic inflammation. There are also significant comorbidities associated with psoriasis, including a 58% risk of cardiovascular disease and 43% increased risk of stroke. The risk of diabetes is 30% higher in patients with severe psoriasis.

Multipotential/Mesenchymal adult stem cells (MSCs) are currently being studied by USRM in a variety of diseases and injuries. MSCs can be found in many tissues throughout the body and are thought to play a critical role in a patient’s healing cascade. When MSCs are placed into culture or in vitro, they demonstrate an ability to differentiate on several different tissue pathways. MSCs are part of the body’s natural healing mechanism and as such represent a potential therapy in a variety of diseases, including having immunomodulatory properties and stimulating a healing response by reducing inflammation. For this reason, MSCs may be beneficial for patients experiencing excessive inflammation, as is present in autoimmune diseases like psoriasis.

Dr. Comella, who has more than 20+ years’ experience, is recognized worldwide by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies.  She has also been instrumental in developing and bringing to market USRM’s proprietary AdipocellTM product, a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat, a naturally occurring tissue in the body which happens to contain a robust supply of stem cells.  

USRM has been involved in more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 287 clinics.  

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516.

Helmick CG, Lee-Han H, Hirsch SC, Baird TL, Bartlett CL. Prevalence of psoriasis among adults in the U.S: 2003–2006 and 2009–2010 national health and nutrition examination surveys. Am J Prevent Med. 2014;47(1):37–45.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

USRM Chief Science Officer to Present at Paleo f(x) Ancestral Healing Conference in Austin, Texas

SUNRISE, FL – March 20, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, is pleased to announce its Chief Science Officer, Dr. Kristin Comella, has accepted an invitation to present at the 2018 Paleo f(x) Ancestral Healing Conference Friday, April 27, at the Palmer Events Center in Austin, Texas.

Dr. Comella will present “Regenerative Medicine: The Future of Medicine is Here,” at 4:25 p.m. CST at the Kegenix Paleo On Ramp Stage.  Her presentation will be livestreamed on the USRM facebook page, follow to receive a live notification.

Dr. Comella will also participate in a Mastermind Panel entitled “Alt-Med: New Paradigms in Health and Wellness,” with several other world leaders in innovative health, including Dr. Joseph Mercola, Neurologist Dr. David Perlmutter, Naturopath Dr. Harry Adelson, epigenetic pioneer Dr. Ben Lynch and functional medicine expert Dr. Michael Ruscio, on Friday, April 27 at 5:35 p.m. CST at the ID LifeWellness Keynote Stage.  The topic will explore how traditional western medicine has been undeniably successful in battling communicable diseases and acute trauma, but how do we navigate its failure to deal with the diseases of modernity that plague us now?

“I am honored to have the opportunity to participate in the Paleo f(x) conference with such esteemed colleagues, and to share with the audience and other world innovators our latest developments on autologous stem cell therapy and stromal vascular fraction,” said Dr. Comella.  “It will be a pleasure to participate in this conference, which will feature a very interesting presence of leading health practitioners from around the world.”

Dr. Comella, who has more than 20+ years’ experience, is recognized worldwide by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies.  She has also been instrumental in developing and bringing to market USRM’s proprietary AdipocellTM product, a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat, a naturally occurring tissue in the body which happens to contain a robust supply of stem cells.  

Once harvested, through a minimally invasive liposuction procedure that is performed while the patient is comfortable but fully awake, the stem cells are then re-injected intravenously or applied directly to a damaged tissue for a more targeted application.  

In January, the Company announced AdipocellTM reached sales of 10,000+ kits worldwide.

Autologous stem cell treatments harvested from the patient’s own fat can provide healthier alternatives to the use of pharmaceuticals for treating chronic pain and degeneration.  Chronic pain has been the source of a national opioid epidemic which The New York Times reported in October is the leading cause of death for Americans under 50.

USRM has been involved in more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 287 clinics.  

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

USRM Chief Science Officer to Present at Academy of Regenerative Practices Conference

SUNRISE, FL – February 28, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, announces our participation in this year’s fourth annual Academy of Regenerative Practices’ Conference, which kicks off tomorrow and continues through March 2 & 3 at the Bonaventure Resort & Spa in Weston, Florida.

The Conference, which hosts some of the world’s leading regenerative scientists, health and medical professionals — including USRM’s Chief Science Officer & ARP President Dr. Kristin Comella — will feature more than 29 speakers including  Dr. Joseph Mercola, Dr. Josh Axe & Ben Greenfield.

The annual event also provides doctors and physicians the opportunity to receive hands-on, accredited, continuing education training in performing stem cell procedures.  Doctors are able to gain the ability to augment their practice with this cutting-edge, regenerative therapy — a process that is becoming increasingly in demand amongst the patient population in the United States suffering from neurological, autoimmune, orthopedic and degenerative conditions.

Dr. Comella will be presenting a summary of peer-reviewed publications using a stem cell procedure called Stromal Vascular Fraction (SVF), on Saturday, March 4, at 8:40 a.m.  She is well published in the scientific literature through her work at USRM on the application of stem cells and regenerative therapy, including integrating stem cells to improve knee function in cartilage damaged by osteoarthritis; a phase I clinical trial for the use of autologous stem cells in the treatment of end-stage chronic obstructive pulmonary disease; intraglandular injection of stem cells for the treatment of irradiation-induced gland damage post cancer, and the effects of the use of stem cells in patients with chronic ischemic cardiomyopathy.

Dr. Comella, who has more than 20+ years’ experience, is recognized worldwide by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies.  She has also been instrumental in developing and bringing to market USRM’s proprietary AdipocellTM product, a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat, a naturally occurring tissue in the body which happens to contain a robust supply of stem cells.  Once harvested, through a minimally invasive liposuction procedure that is performed while the patient is comfortable but fully awake, the stem cells are then re-injected intravenously or applied directly to a damaged tissue or gland for a more targeted application.  

In January, the Company announced AdipocellTM reached sales of 10,000+ kits worldwide.

“It’s always such a pleasure to gather with this rapidly expanding community of scientific experts to connect and collaborate,” said Dr. Kristin Comella, USRM’s Chief Science Officer and President of the Academy of Regenerative Practices.  “This is an incredible time for regenerative medicine, and connecting with my colleagues in the scientific community who are passionate about it is always such a treat.  I look forward to another successful conference with my colleagues from around the world.”

Autologous stem cell treatments harvested from the patient’s own fat can provide healthier alternatives to the use of pharmaceuticals for treating chronic pain and degeneration.  Chronic pain has been the source of a national opioid epidemic which The New York Times reported in October is the leading cause of death for Americans under 50.

USRM has been involved in more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 287 clinics.  

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

 

Read More

USRM Posts Live Webinar with World Renowned Biohacker

Enhancing Sexual Performance with Stem Cell Therapy’ Available for Playback

SUNRISE, FL – Feb. 20, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has posted a live playback of its Saturday webinar here, “Enhancing Sexual Performance with Stem Cell Therapy —  an informative Q & A with USRM Chief Science Officer Dr. Kristin Comella and leading biohacker and CEO of health company Kion, Ben Greenfield, who recently had penile stem cell injections to enhance sexual performance.

Greenfield, who recently received stromal vascular fraction treatments (SVF) intravenously for overall bioenhancement, as well as penile injections for erectile enhancement, says as a result of the treatments his overall healing function as well as sexual performance has been significantly enhanced.

“I’ve done IV stem cells as well as knee and hip joint.  It took about 5 to 7 days to kick in.  I went from being laid up and injured to almost being 100% ready for race season,” says Greenfield, who regularly participates in Ironman and other endurance races.  Regarding autologous, IV stem cell injections, Greenfield stated “It’s a huge increase in energy… a clear head, less of a need to nap in the afternoon, better workouts and workout recovery — an improved overall sense of well-being.  With penis injection … it took about 3 to 4 days to kick in and the main things I noticed were significant increase in erectile function, a significant increase in size in what we call ‘at rest,’ better orgasms, better blood flow — the anatomical manifestations cannot be denied.”

“Ben’s experience is a perfect example of someone who is using stem cell therapy proactively, to enhance physical performance at a very high level,” said Dr. Kristin Comella, USRM’s Chief Science Officer.  “His testimony is a terrific way for patients interested in learning more about the process to get a front row seat, even in the playback the questions and answers can be beneficial for those who are interested in the process.”

SVF involves using USRM’s proprietary AdipocellTM kit to help isolate a patient’s own stem cells from their fat cells. Studies of stromal vascular fractions used in ED therapy are starting to emerge, as is documented in a scientific paper featured in EBioMedicine’s January 2017 issue.

Autologous stem cell treatments harvested from the patient’s own fat could provide healthier alternatives to the use of pharmaceuticals for erectile enhancement and dysfunction (ED) — a worldwide market that is estimated to be more than $4 billion annually and has slowed in growth due to toxic side effects from pharmaceuticals currently on the market, according to a report by Grand View Research published in July 2016. As a result, more men and women are seeking out stem cell therapy to enhance sexual performance, which to date has yielded more than 35 scientific studies about stem cell therapy and sexual enhancement.

Enhancing Sexual Performance with Stem Cells,” is the second in a series of webinars by USRM and Dr. Comella, dedicated to educating, informing and demystifying the public about the practice of regenerative stem cell therapy.  The first webinar, “Facts About Stem Cell Therapy,” which was broadcast live Feb. 9, can be accessed as a playback here.

Dr. Comella, who has more than 20+ years’ experience and is one of the world’s leading stem cell scientists, is also featured in the recent Jeff Hays docuseries “The Healing Miracle: The Truth About Stem Cells.” (Click here to view Dr. Comella’s interview from THM in its entirety.)  It was her participation in the docuseries that inspired her to launch the webinar series.

Greenfield, who was voted in 2013 and 2014 as one of the world’s top 100 most influential people in health and fitness by Greatist, coaches top CEO’s, chefs, biohackers, endurance competitors, and professional athletes from the UFC, NHL, NBA, NFL and beyond – all while advising and investing in top companies in the health, fitness and nutrition industries. He was voted in 2008 as Personal Trainer of the Year by the National Strength and Conditioning Association (NSCA), and is a regular contributor to Huffington Post. He is also the CEO of Kion Health and hosts the highly popular Ben Greenfield Fitness podcast, one of the top-ranked health and fitness podcasts in iTunes. He has a bachelor’s degree and master’s degree from University of Idaho in sports science and exercise physiology and personal training, plus strength and conditioning certifications from the NSCA.

USRM has been involved in more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 287 clinics.  Dr. Comella is well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies.  She has also been instrumental in developing and bringing to market USRM’s AdipocellTM, a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

CEO Blog: February 2018

Dear Shareholders and Friends,

Thank you all so much for taking the time to learn more about our recent progress.  In this post, we want to take a moment to share key highlights from 2017, as well as update you with new developments for 2018.

A strengthening economy, an increase in marketplace demand as more people learn about stem cell treatments and alternatives to opioids, and an increase in more doctors and physicians advancing their skill sets to include stem cell treatments are all reasons why we are beginning to see steady growth.  

We are pleased to announce that our proprietary AdipocellTM stem cell kit has reached 10,000 units in sales — an indication that the marketplace is starting to demand stem cell therapy more readily.  Although we reached the goal in January of 2018, much of the effort behind attaining that benchmark was done in 2017, and our hard work is paying off.

We are also proud to announce we have completed more than 10,000 stem cell procedures since 1999 for a variety of indications — including orthopedic, autoimmune, degenerative and neurological diseases.  We are pleased to share that, to-date, we have trained more than 700 physicians worldwide on stem cell therapy, and we anticipate that number will only continue to increase.

The FDA’s issuance of guidance documents in November of last year also has also signaled to the marketplace the legitimacy of stem cell therapy as a practice.  Because our science is based on the use of a patient’s own (autologous) stem cells, we are confident that the issuance of these guidance documents moves us closer to a time when there will be clear differentiation between treatments that are autologous, versus those that involve the use of donated, off-the-shelf, third-party stem cells that may or may not have been genetically manipulated and clearly require more regulation.   

USRM is working with one of the best legal teams based in Washington, D.C., to help communicate with the FDA while preserving the rights of patients to harness their bodies’ own healing potential.  We have joined forces with the Academy of Regenerative Practices to ensure that our physicians have a right to practice regenerative medicine with their consenting patients.  We are proud sponsors of the upcoming ARP annual conference March 1st – 3rd where our Chief Science Officer Dr. Kristin Comella will be a keynote speaker.

Demand for stem cell therapy is anticipated to be at an all-time high this year, as more patients seek the growing trend of using their own cells to heal various injuries and diseases.  As a result, we have expanded our clinic locations to include West Palm Beach. This expansion is timely, given the emerging and explosive demand now coming from patients and the marketplace.   We have worked very hard as a team to temper our growth in order to be ready to meet the demands of a growing market at just the right time.  We are confident that timing is now.

USRM technologies are now offered in six continents with interest from various countries throughout the world growing.  We have experienced a few delays with our facilities opening in Kuwait due to unforeseen regulatory hurdles.  These types of challenges are very familiar to us, we know it is part of the landscape and we know how to address them.  We will continue to work with our legal team to neutralize these concerns and move forward with bringing stem cell treatments to the patients in the Middle East.

The recent opioid crisis in America means more patients are seeking alternative therapies to pharmaceuticals and surgery for coping with and managing chronic pain.  Stem cell therapy may offer new solutions for these patients experiencing systemic diseases, orthopedic conditions, neurological symptoms and other therapies for an aging population.  Shape Magazine discusses this subject in their most recent issue, where they mention Dr. Kristin Comella and her work with autologous stem cells.  Shape Magazine is the first of many highly-visible mentions where Dr. Comella has been featured, including “The Healing Miracle: The Truth About Stem Cells,” a docuseries that interviews renowned experts in the field of stem cell medicine and explores in-depth the benefits and application of regenerative stem cell therapy.  Dr. Comella is featured in Episode five of the docuseries; that interview can be viewed in its entirety here.  

Due to the overwhelming response we have had as a result of that docuseries, we were inspired to launch our own live webinar series in order to educate and inform our audience, as well as provide a forum for Q & A on an anonymous platform.   Facts About Stem Cell Therapy,” which had its first live broadcast February 9th, was very well received and had more than 100 participants.  Dr. Comella answered questions live for nearly two hours, which is another demonstration of the growing demand for information about this emerging, holistic, regenerative therapy. If you are interested in joining our mailing list to receive notification for our next stem cell webinar, click here.

In honor of Valentine’s Day and the month of love, our second webinar was broadcast live February 17th and featured Dr. Comella and fitness expert and world renown leading biohacker Ben Greenfield.  The webinar, which is entitled Enhancing Sexual Performance with Stem Cell Therapy,” provides the opportunity to learn more about stem cell therapy and enhancing sexual performance.  Greenfield, who recently underwent penile enhancement with stem cell therapy, documented his journey in the January issue of Men’s Health magazine.  He was successful at increasing both size and rate of performance.  To listen to that webinar in its entirety click here.

Our commitment to this emerging science is unwavering and we will continue to expand efforts to help patients maximize their health with this amazing technology.  We thank you for your interest and continued support and welcome the chance for an ongoing dialogue to answer any questions you may have.

Warmest regards,

Mike Tomas,

President and CEO

Read More

USRM CSO to Host Live Stem Cell Info Webinar with World Renowned Biohacker

‘Discussing Enhancing Sexual Performance with Stem Cell Therapy’ Feb. 17 at Noon

SUNRISE, FL – Feb. 14, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr. Kristin Comella, will host a live webinar open to the public with Ben Greenfield — a leading biohacker and fitness expert and CEO of health company Kion— who recently had penile stem cell injections to enhance sexual performance.

Enhancing Sexual Performance with Stem Cell Therapy,” will be a live-streamed discussion and Q & A with Dr. Comella and Greenfield Saturday, Feb. 17, at Noon EST.  To participate in the webinar, please register by clicking on the link here: https://attendee.gotowebinar.com/register/7172776642688626689.

Greenfield, a self-professed ‘biohacker’ who recently received stromal vascular fraction treatments (SVF) for erectile enhancement as part of his ongoing exploration of optimal physical performance, including penile enhancement, says as a result of the treatment he has experienced penile enlargement and more frequent erections.  

“My drive to discover cutting-edge therapies is what led me to U.S. Stem Cell, and my results certainly convinced me of the validity of this treatment,” said Greenfield. “The opportunity to dictate our own therapies to enhance performance in all arenas of health is an empowering part of physical performance, and it is a demonstration that regenerative medicine is here now.”

“Because so many patients are seeking holistic alternatives to sustain sexual performance, and because it’s Valentine’s Day, we thought it would be the perfect opportunity to discuss the use of autologous stem cells in this arena,” said Dr. Kristin Comella, USRM’s Chief Science Officer.  “Ben’s experience and his willingness to be open about sharing his journey will give a lot of people the opportunity to ask questions in an anonymous setting, so that they can learn more about whether the benefits of SVF is right for them.”

SVF involves using USRM’s proprietary AdipocellTM kit to help isolate a patient’s own stem cells from their fat cells. Studies of stromal vascular fractions used in ED therapy are starting to emerge, as is documented in a scientific paper featured in EBioMedicine’s January 2017 issue.

Autologous stem cell treatments harvested from the patient’s own fat could provide healthier alternatives to the use of pharmaceuticals for erectile enhancement and dysfunction (ED) — a worldwide market that is estimated to be more than $4 billion annually and has slowed in growth due to toxic side effects from pharmaceuticals currently on the market, according to a report by Grand View Research published in July 2016. As a result, more men and women are seeking out stem cell therapy to enhance sexual performance, which to date has yielded more than 35 scientific studies about stem cell therapy and sexual enhancement.

Enhancing Sexual Performance with Stem Cells,” is the second in a series of webinars by USRM and Dr. Comella, dedicated to educating, informing and demystifying the public about the practice of regenerative stem cell therapy.  The first webinar, “Facts About Stem Cell Therapy,” which was broadcast live last Friday, can be accessed as a playback here.

Dr. Comella, who has more than 20+ years’ experience and is one of the world’s leading stem cell scientists, is also featured in the recent Jeff Hays docuseries “The Healing Miracle: The Truth About Stem Cells.” (Click here to view Dr. Comella’s interview from THM in its entirety.)  It was her participation in the docuseries that inspired her to launch the webinar series.

Greenfield, who was voted in 2013 and 2014 as one of the world’s top 100 most influential people in health and fitness by Greatist, coaches top CEO’s, chefs, biohackers, endurance competitors, and professional athletes from the UFC, NHL, NBA, NFL and beyond – all while advising and investing in top companies in the health, fitness and nutrition industries. He was voted in 2008 as Personal Trainer of the Year by the National Strength and Conditioning Association (NSCA), and is a regular contributor to Huffington Post. He is also the CEO of Kion Health and hosts the highly popular Ben Greenfield Fitness podcast, one of the top-ranked health and fitness podcasts in iTunes. He has a bachelor’s degree and master’s degree from University of Idaho in sports science and exercise physiology and personal training, plus strength and conditioning certifications from the NSCA.

USRM has been involved in more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 287 clinics.  Dr. Comella is well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies.  She has also been instrumental in developing and bringing to market USRM’s AdipocellTM, a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

USRM Successfully Launches Stem Cell Webinar Series

Open to Global Participation, More than 100 Attendees in First Q & A

SUNRISE, FL – Feb. 12, 2018 – Dr. Kristin Comella, Chief Science Officer of U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the successful launch of an open, livestream webinar series designed to inform and educate the public on the benefits and applications of stem cell therapy.

Facts About Stem Cell Therapy,” which had its first live broadcast last Friday and includes a question & answer session from more than 100 patients and physicians around the world, continued for nearly two hours while live streamers posted questions to Dr. Comella about the application of autologous stem cells therapy.   Such a strong, positive response demonstrates the growing demand for information about this emerging, holistic, regenerative therapy.

Playback of the webinar can be accessed here:

http://www.brainshark.com/Stemlogix/vu?pi=zHEz136Dfmz5OLvz0.

Dr. Comella will be hosting a second livestream webinar Saturday, Feb. 17, at 12 noon EST (Click here to register).  In honor of Valentine’s Day and the month of love, her featured guest will be fitness expert Ben Greenfield, who recently underwent stem cell therapy for erectile enhancement — a multi-million-dollar industry that is increasing in patient population but is underserved, mainly due to side effects associated with erectile dysfunction pharmaceuticals currently on the market.

“The webinar platform gives us the perfect opportunity to make the concept of autologous stem cell therapy accessible to the world,” said Dr. Comella.  “It also enables audience participation in a manner that allows for privacy.  I read the questions to the audience, so we maintain privacy from the inquisitor while simultaneously providing the opportunity for a comprehensive teaching moment, even in playback.  It’s a perfect way to help people learn more about this incredible form of healing.”  

Dr. Comella, who has more than 20+ years’ experience and is one of the world’s leading stem cell scientists, is also featured in the recent Jeff Hays docuseries “The Healing Miracle: The Truth About Stem Cells.” (Click here to view Dr. Comella’s interview from THM in its entirety.)  It was her participation in the docuseries that inspired her to launch the webinar series.

“Dr. Comella is a natural — her passion is contagious and her expertise in stem cell therapy is unparalleled,” said Mike Tomas, Chief Executive Officer of U.S. Stem Cell, Inc.  “Because demand has been so strong at our clinics, as more and more people are learning about stem cell therapy as an alternative to pain management, the webinar format gives us the opportunity to reach more people faster, and to meet the demand for more specific information in a really efficient and effective way.”

USRM has been involved in more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 287 clinics.  Dr. Comella is well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies.  She has also been instrumental in developing and bringing to market USRM’s AdipocellTM, a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

USRM Seeing Explosive Increase in Demand for Stem Cell Therapy

Failure of Opioids & Economic Growth Driving Force,

CSO to Host Live Info Webinar

SUNRISE, FL – Feb. 6, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it is experiencing explosive demand for stem cell treatments at its clinics — a trend that is reflected in the 106% increase in revenues during the 3rd Q and is continuing as a result of rapidly increasing demand from the marketplace.

As a result, USRM Chief Science Officer Dr. Kristin Comella, who is featured in the docuseries, “The Healing Miracle: The Truth About Stem Cells,” will be hosting a live webinar Friday, Feb. 9, to help answer questions about stem cell therapy and treatments.

“Our phones are ringing off the hook,” said Dr. Comella.  “Public demand is ramping up quickly, as Americans invest in educating themselves on stem cell therapy and alternatives to opioid protocols for chronic pain.  Moreover, because stem cell therapy is an out-of-pocket expense, improved economic indicators are giving Americans more money in their pockets for discretionary spending, which is increasing opportunity for stem cell treatments,” said Dr. Comella.

Total revenue for 2017, which will be announced in mid March when the company files its 10k, is expected to increase from 2016.

“We have seen significant revenue increases for the past six straight quarters and market demand is starting to drive revenue even further” said Mike Tomas, Chief Executive Officer of U.S. Stem Cell, Inc.  “We look forward to sharing news of our continued growth and are pleased to see 2018 is starting off so well with the recent milestone of reaching 10,000 units sold for our proprietary AdipocellTM product,” said Tomas.  “We believe this is an indicator of continued growth to come.”

Dr. Comella, who has more than 20+ years’ experience and is one of the world’s leading stem cell scientists, can be seen in The Healing Miracle docuseries here.  To view Dr. Comella’s interview online, click the link and fill out the information, which will provide complimentary access.

To access Dr. Comella’s live webinar this Friday, Feb. 9, at Noon EST, click here to register or join.  Details of the webinar, along with a playback link after it is broadcast, will also be posted on the company’s website and its Facebook page (https://www.facebook.com/USStemCellInc/).

USRM has been involved in more than 10,000 stem cell procedures since 1999 for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 287 clinics.  Dr. Comella is well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies.  She has also been instrumental in developing and bringing to market USRM’s AdipocellTM, a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years; has more than 287 clinics using its proprietary technology and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

USRM Chief Science Officer Featured in Powerful Stem Cell Docuseries

SUNRISE, FL – Jan. 24, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr. Kristin Comella, has been featured in the docuseries, “The Healing Miracle: The Truth About Stem Cells” — a film that interviews renowned experts in the field of stem cell medicine and explores in-depth the benefits and application of regenerative stem cell therapy.

Dr. Comella, who has more than 20+ years’ experience and is one of the world’s leading stem cell scientists, has been involved in more than 10,000 stem cell procedures at USRM since 2001.  USRM has pioneered stem cell therapy for damaged tissue from a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide —  and has engaged with more than 287 clinics.  Dr. Comella is well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies.  She has also been instrumental in developing and bringing to market USRM’s AdipocellTM , a stem cell kit which enables physicians to separate stem cells from a patient’s own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.

In the documentary, Dr. Comella (who has worked with all kinds of stem cells including, bone, muscle and fat), recounts an emotional experience with a patient who presented with a two-year-old head trauma and was wheelchair bound.   Following her stem cell protocol with Dr. Comella and USRM, she had a life-changing experience.

Americans in general have been relatively uninformed about the availability of the field of stem cell therapy and regenerative medicine as an option for treating chronic pain conditions, damaged tissue and life-threatening illness. ‘The Healing Miracle,’ which is produced by Jeff Hays Films, is on a mission to change that trend by shining a light on a field of medicine that has been somewhat sidelined by U.S. regulatory agencies.  Last November, the FDA issued a long-awaited statement indicating it is moving toward integrating stem cell therapy into its code of practice, but concluded by giving itself three years to determine whether it will heavily regulate stem cells in humans as drugs, or continue to allow individuals to have free access to their own healing reserves of stem cells.

“The purpose of this interview is to educate people about cellular medicine — a concept that has been overshadowed by a pharmaceutical industry that has used disassociation and fear to distract patients from their own healing capabilities,” said Dr. Comella.  “This documentary is a great way for the public to learn more about regenerative options available to them —  an alternative to chronic, long-term drug use to managing symptoms, which we all know is often accompanied by debilitating side effects.  There has never been a better time to bring this forward than now, to explore healing regenerative therapies… facing a national emergency around pain management and opioid misuse is a clear wake up call that it’s time for better methods.”

Dr. Comella is featured in episode 5 of the docuseries, which is available in its entirety online.  To watch just Dr. Comella’s interview, click the Brainshark link here and fill out the information which will provide complimentary access.

“We are so proud of Dr. Comella. The world’s growing interest in her work and about stem cell therapy and regenerative medicine is an indication our time has come,” said Mike Tomas, President and CEO of U.S. Stem Cell, Inc. “Stem cell therapy is rapidly becoming a part of mainstream medicine, and USRM is poised to take the lead in offering this treatment worldwide.”

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years, and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide. 

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

USRM Reaches Key Sales Milestone of Proprietary Adipocell TM Product

Company Poised to Be Industry Leader in Autologous Adipose Stem Cell Treatments

SUNRISE, FL – Jan. 15, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has reached a key milestone of 10,000 kit sales of its proprietary Adipocell TM product, a direct result of its relationships with 287 clinics in the United States and 700+ physicians worldwide offering USRM’s proprietary stem cell products and services.

Adipocell TM , which has been developed, marketed and distributed by USRM, enables physicians to separate potent stem cells from a patient’s own (autologous) fat cells, which are harvested and reinserted in two-hours total, in a minimally invasive procedure. Stem cells are an important component of the body’s ability to regenerate itself, and are rapidly becoming a mainstream trend in the field of regenerative medicine.

USRM is the premiere company in the United States that markets and manufactures an autologous adipose/stem cell separation kit. Autologous cells are not rejected by the body’s immune system and, as a result, may be more compatible and effective in reversing damage and augmenting health.

In addition to trailblazing the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, USRM also has developed a training program for physicians who want to learn how to offer stem cell therapy to their patients.

In-person training involves a two-day, interactive, hands-on training course at USRM’s Sunrise, Florida-based clinic, and includes integration of autologous cellular treatments, the extraction of lipoaspirate and bone marrow aspirate, as well as demonstrations on how to isolate adipose and bone-marrow-derived stem cells. Physician trainees will participate in several cases and perform clinical procedures under the supervision of an experienced instructor on a total of 3-5 patients. Cost for physician participation is $7,500.

Online training offers physicians clinical training in a web-based format. Consistent with in-person training, online training focuses on autologous cellular treatments like adult stem cells and platelet-rich plasma. Physicians will learn the basics of stem therapy and have the option to obtain preceptor on-site training. Cost for physician participation is $2,500.

On-site training is available for physicians who have completed in-person or online training, and involves a USRM stem-cell specialist providing the physician one-on-one, on-site training at the physician’s own clinic.

“This is a key milestone for us as a Company, and for regenerative medicine in general, as it demonstrates the increasing demand in the marketplace for our AdipocellTM product,” said Mike Tomas, President and CEO of U.S. Stem Cell, Inc. “We are dedicated and proud to lead the way on a global scale for the emergence of this novel therapeutic.”

“Our commitment to making regenerative, stem cell therapy available to any physician worldwide who is interested in providing stem cell therapy to their patients is reflected in our day-to-day practices as an organization,” said Dr. Kristin Comella, Chief Science Officer for U.S. Stem Cell, Inc. “The need for readily available stem cell procedures that physicians can offer their patients as an alternative to addictive pain medications, which has caused an opioid crisis in America, proves the time for regenerative medicine as a part of regular physician practice and pain management is long overdue.”

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years, and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

On a Mission to Obtain Optimal Health from the Inside Out

I have dedicated my life and career to health and the optimization of the body, and I have made it my life’s work to share this passion with others. The discovery of my natural abilities in math and science at an early age identified for me this opportunity. It is my privilege to harness and share my talent and apply it to the world’s greatest machine: the human!

I started out as a young leader actively participating as a swim and gymnastics coach at the YMCA when I was 15 years old. My appreciation for the human body and what it is capable of performing at its optimal level quickly traversed into leading group fitness classes and education. When I am not in the laboratory or meeting patients at our U.S. Stem Cell Clinic, I continue that passion for educating and leading others in fitness and health to this day. I have always enjoyed the science of health on every level, and continue to identify, develop and incorporate the latest research in my day-to- day activities for my participants to fully enjoy the human experience.

After graduating high school from the Academy of Holy Names in Tampa, Florida, with a near perfect transcript and the highest honors in both math and science, I decided to pursue Chemical Engineering at the University of South Florida. In addition to the required Engineering curriculum, I specialized in the honors program with a biology emphasis. Chemical Engineering is the study of processes, and I purposely chose this curriculum to apply my understanding of processes to the human body. The systems and the cycles in the human body are more complex and spectacular than any man-made machine on earth! Applying complex engineering to this system could provide me the perfect foundation for unlocking the secret to longevity. I graduated a year ahead of my class as an honors student with a Bachelors of Science degree, my senior thesis being a project in Biomedical Engineering.

I knew my journey was just beginning and decided to attend graduate school at The Ohio State University Chemical Engineering program. This program was listed as one of the top in the United States and it gave me the incredible opportunity to work with Dr. Jeffrey Chalmers in his cell culture and bioengineering lab. My research during my time at Dr. Chalmers’ lab focused on the use of nano-particle magnets to isolate and separate cells. While at the University, I completed all necessary PhD course work and defended generals while publishing several studies on magnetic cell sorting. I also had the opportunity to work with Dr. Maciej Zborowski of the Cleveland Clinic Biomedical Engineering program. With approximately one year until PhD completion, I had the good fortune to join a small startup company in Maryland called Osiris Therapeutics. During this time same time, my husband and I were also expecting the joyous arrival of our first child.

In 2001, I made the decision to finish my master’s thesis and join Osiris founded by Dr. Arnie Caplan (the ‘Father of the Mesenchymal Stem Cell’).  I worked as a research engineer with Drs. Frank Barry and Mary Murphy and 2 other scientists on the Chondrogen team.  We were studying the use of mesenchymal stem cells (MSCs) from bone marrow for an application in the knee joint.  Pursuing one of the first investigational new drug (IND) applications to the FDA for MSCs, we completed several pre-clinical studies in large animal models.  My responsibilities included developing and implementing cell culture expansion protocols and testing of the cells in vivo.  I remember the day I was working with another scientist to score the cartilage growth present in goat knee joints after stem cell injection and thinking, ‘wow, this is going to change medicine as we know it!’  These preclinical studies were used to successfully obtain one of the first IND approvals of stem cells in orthopedics from the FDA in 2002.  

At this point in time, another amazing opportunity was presented to me — this time to move to Tulane University in New Orleans and work with Dr. Darwin Prockop (the grandfather  of cellular therapy research on mesenchymal progenitors, such as MSCs).  I was hired as the manager of the FDA Good Manufacturing Practices (GMP) facility at Tulane’s Center of Gene Therapy. Our focus was using MSCs for applications in spinal cord injuries.  It was my responsibility to design and implement all GMP compliant protocols for isolation, expansion and implementation of stem cells in patients with spinal cord injuries.

In 2004, shortly after the birth of my second child, another door opened — this time to move to Florida to join a growing start-up called Bioheart, Inc. now, U.S. Stem Cell, Inc.  Our focus was the pursuit of solutions to one of the greatest challenges in health care: Heart Disease.  I worked with Dr. Doris Taylor who has published some of the earliest studies on muscle stem cells in the heart in animal models.  My challenge was to make this therapy ready for the clinic for use in our US and European clinical trials.  I traveled the world supplementing my knowledge base by learning from other experts in heart science and medicine, including spending a month in Navarro, Spain, working with Dr. Felipe Prosper (head of the Cellular Therapy Unit at the Clinica Universidad de Navvarra).  I developed and more closely perfected the manufacturing of muscle stem cells for use in humans suffering from congestive heart failure.  We worked side by side with top cardiologists including Drs. Tim Henry, Warren Sherman, Thomas Povsnic, Chris O’Connor and more, at leading centers worldwide to successfully provide this treatment to hundreds of patients.  We even published the first double blind placebo controlled trial demonstrating safety and preliminary efficacy of the injection of muscle stem cells into the heart.

It was during 2007 that our company became very interested in Adipose Derived Stem Cells (ADSCs), and I was given the opportunity to train with Dr. Stu Williams who is often credited as one of the first researchers in ADSCs.  Our focus began with the implementation of clinical programs using adipose cells or, more specifically, stromal vascular fraction or SVF (population of cells from adipose tissue with fat cells removed).  We started studies in the India, Mexico and the Czech Republic.  It quickly became obvious that these diverse cells could be used in a variety of indications and, because this is a medical procedure fully implemented at point of care, the therapies did not suffer the same regulatory scrutiny normally involved in a culture expanded cell procedure.

I worked with physicians from a variety of sub specialties in order to establish protocols to utilize these cells to promote healing and reverse tissue damage.  We developed and established an in-clinic protocol that could be completed in under 2-3 hours — unheard of at this point in time in medical practice.  In collaboration with our team and outside medical professionals, we have completed and published more patient therapies using SVF than anyone in the world.   These protocols have helped thousands of patients heal naturally without the side effects of pharmaceutical drugs, utilizing a cellularly holistic approach that is more in harmony with a patient’s individual cellular landscape.  Also, together with a team of medical professionals, I developed a training program to help other physicians understand how to implement these therapies on a broader scale, in order to bring this novel therapeutic procedure to the world.  

In 2014, I started an organization called the Academy of Regenerative Practices in order to bring together medical professionals and scientists seeking to help people heal naturally.  The power to heal exists inside every single one of us and we can tap into this regenerative potential!  It is my life’s work to lead the charge of this organization in order to help educate the public about this healing potential, including holding our ground that no agency or corporate entity owns the cells that exist inside our bodies.   We have the right to pursue holistic healing modalities of our choice, with the doctors of our choice, in order to obtain natural healing.

I have had the honor and privilege at this point in time of being recognized by my peers on several occasions:  I was chosen number 24 on Terrapin’s list of the Top 50 Global Stem Cell Influencers  and number 1 on the Academy of Regenerative Practices list of Top 10 Stem Cell Innovators. Most recently, I was named in the Top 50 Functional and Integrative Medical Doctors/Scientists in the country by DrAxe.com — one of the most visited natural health websites in the world.  I am humbled by the accolades but keep my eye on the prize, which is reinforced daily by my morning mantra: What can I do today to get stem cell treatments to as many people as possible?

A few years ago, I made the decision to return to school and complete my PhD.  After finishing additional coursework at Florida International University, publishing studies on the use of stem cells in osteoarthritis, finalizing a book chapter on bioreactors and the largest safety study on the use of SVF, I am proud to say that I have finally completed my PhD in Stem Cell Biology from the Panama College of Cell Science.

As stem cell therapies continue to gain in popularity, my role as a patient advocate has become my life’s work.  I am on a mission to obtain health from the inside out, and to help people in this world accomplish this for themselves.  When you bring forward a technology that is so innovative and groundbreaking it is considered ‘disruptive,’ the terrain can be rocky.  After all, these novel therapies are literally changing the course of medicine forever.  Groundbreakers always attract naysayers, it’s just a universal truth.  I understand and accept the challenges associated with being a groundbreaker, and I will never stop fighting for the right for individuals to use their own cells to heal.

I am a dedicated wife and mother of two amazing teenagers.  I am a scientist who continues to focus her career on helping others achieve health.  I have the honor of working with some of the best and brightest minds in the world.  I am Kristin Comella and I’m on a mission to help others obtain health from the inside out.

Read More

USRM Stem Cell Treatment Shows Promise in Enhancing Erectile Function

World-Renowned Athlete Receives Treatment, Featured in Men’s Health Magazine

SUNRISE, FL – Jan. 8, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced world-renowned fitness expert Ben Greenfield successfully received its stromal vascular fraction treatment for erectile enhancement. Details of the procedure and the results are featured in the January issue of Men’s Health, on newsstands now.

Greenfield, whose experience following the treatments includes more frequent erections and penile enlargement, received his first of two treatments at the USRM clinic in Sunrise, Florida.

Stromal vascular fraction treatments, or autologous stem cell treatments harvested from the patient’s own fat, could provide healthier alternatives to use of pharmaceuticals for erectile enhancement and dysfunction (ED) — a market that is estimated to be more than $4 billion annually and has slowed in growth due to toxic side effects from pharmaceuticals currently on the market, according to a report by Grand View Research published in July 2016. Greenfield, who is a self-professed ‘biohacker,’ sought treatment as part of his ongoing exploration of ‘biohacking’ and penile enhancement. “My drive to discover cutting-edge therapies is what led me to U.S. Stem Cell, and my results certainly convinced me of the validity of this treatment,” said Greenfield. “The opportunity to dictate our own therapies to enhance performance in all arenas of health is an empowering part of physical performance, and it is a demonstration that regenerative medicine is here now.”

Stromal vascular fraction involves using USRM’s proprietary AdipoCellTM kit to help isolate a patient’s own stem cells from the fat cells. Studies of stromal vascular fraction’s used in ED therapy are starting to emerge, as is documented in a scientific paper featured in EBioMedicine’s January 2017 issue.

“Autologous stem cell therapy is rapidly entering the arena of mainstream regenerative medicine, as is exemplified by its acceptance, use and promotion by cutting edge biohackers and fitness experts like Mr. Greenfield,” said Dr. Kristin Comella, USRM’s Chief Science Officer. “As regenerative stem cell therapy continues to expand into specialized markets, we look forward to broadening our application for these voluntary procedures.”

Greenfield, who was voted in 2013 and 2014 as one of the world’s top 100 most influential people in health and fitness by Greatist, coaches top CEO’s, chefs, biohackers, endurance competitors, and professional athletes from the UFC, NHL, NBA, NFL and beyond – all while advising and investing in top companies in the health, fitness and nutrition industries. He was voted in 2008 as Personal Trainer of the Year by the National Strength and Conditioning Association (NSCA), and is a regular contributor to Huffington Post. He is also the CEO of Kion Health and hosts the highly popular Ben Greenfield Fitness podcast, one of the top-ranked health and fitness podcasts in iTunes. He has a bachelor’s degree and master’s degree from University of Idaho in sports science and exercise physiology and personal training, plus strength and conditioning certifications from the NSCA.

“Last year was about restructuring debt and streamlining our financials in order to position ourselves in 2018 for these kinds of opportunities,” said Mike Tomas, USRM’s Chief Executive Officer. “We look forward to continuing to explore the application of stromal vascular fraction treatments for a wide variety of voluntary procedures which is being driven by market demand for more holistic, autologous therapies.”

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product Adipocell TM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years, and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.

###

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward- looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

USRM Responds to Lawsuit Filed for Discontinued Eye Treatments

MIAMI, FL –Dec.20, 2017 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today responded to a lawsuit filed last week in Broward County by a plaintiff claiming she had an adverse event for a voluntary stem cell procedure at a doctor’s office utilizing autologous (the patient’s own) stem cells to attempt to reverse the effects of macular degeneration— a disease that currently has no cure.

The adverse event the plaintiff claims she experienced as a result of the treatment, which was administered by a doctor in February of 2015, is a detached retina in one eye, which the patient alleges has led to loss of sight in that eye. Counsel for the patient also claims that his client’s vision has worsened in the other eye. As the lawsuit was just filed, these allegations have not been corroborated. USRM’s AdipoCell TM kit was used to harvest autologous cells from the patient’s fat tissue.

The use of autologous stem cells for macular degeneration was discontinued by US Stem Cell Clinic, a separate company, as of June of 2015, after adverse events were reported.

“We have addressed any concerns about using AdipoCell TM for macular degeneration by discontinuing its use since more than two years ago,” said Dr. Kristin Comella, USRM’s Chief Science Officer. “Because we have seen strong safety profiles using AdipoCell TM to harvest autologous stem cells to treat a wide variety of other conditions — including orthopedic, autoimmune, degenerative and neurological diseases — we are instead focusing our development at this time on these more broad arenas.”

“Publicly traded companies are always a target for law suits,” said Mike Tomas, President & CEO of U.S. Stem Cell, Inc. “Every lawsuit is different, we are confident that our attorneys — who are very familiar with the issues surrounding this case — will investigate and defend this claim so that this case is resolved as soon as legally practical.”

U.S. Stem Cell and its affiliated entities did not administer the treatment to the patient. The procedure was performed by an outside practitioner, who is among the hundreds of trained doctors worldwide who utilize U.S. Stem Cell, Inc. technology. U.S. Stem Cell does not currently treat eye patients, and for nearly 20 years, clinics have safely conducted thousands of stem cell procedures utilizing our protocol. We remain committed to the development of effective cell technologies to treat patients with a variety of diseases and injuries.

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product Adipocell TM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years, and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.

###

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

CSO Blog: Our 2017 and Direction for the Coming Year

Dear shareholders and friends,

We are reaching the final days of 2017, it has been one more year of progress, challenges and success. This final month continues to be a productive one as we look forward into 2018! I had the honor of presenting this month at the Healthy Masters Worldwide Forum, on Dec. 2, where I discussed “Regenerative Medicine: The Future of Medicine is Here” and reviewed results of a safety study and a knee study. These studies are further evidence of the safety and effectiveness of stem cell procedures that use cells harvested with USRM’s proprietary Adipocell™. These novel therapies, for patients living with degenerative conditions and tissue damage, enable patients to harness their own healing potential and use their very own cells to treat themselves.

As most of you know I am an avid and vocal supporter in the fight for the rights of patients. In fact, I am a patient myself and have received injections using my own stem cells! Our government’s agency, the FDA, has recently acted to limit those rights with new regulations that limit patient access to their own tissue. Were this regulation to interfere with a person’s ability to utilize their own cells to heal themselves, it could be a violation of basic human rights.

Fellow scientists, medical practitioners and I are coming together to defend these rights and the therapies that we know have the potential to help millions of people worldwide for a myriad of indications — from pain management, to wound healing, to neurological conditions and spinal cord injuries as well as tissue regeneration in orthopedic and cardiac diseases. Our efforts, such as the work being done through the ARP Legal Defense Fund, help patients continue to access their own healing potential. Stem cell therapy is changing lives today, and is the exciting future of healthcare .

The FDA recently published two draft guidances regarding Regenerative Medicine Advanced Therapies (RMAT). Based on these draft guidance documents, the FDA will continue to require a robust clinical trial program for these products, which typically costs hundreds of millions of dollars and years of studies. We have spent more than $100 million over two decades on both preclinical (animal) and clinical (human) trials for the MyoCell™ product. We have published many studies showing that the culture-expanded autologous stem cells directly injected into the heart can provide benefit to congestive heart failure patients. We will continue to work closely with the FDA to understand how these new draft guidances will affect our technologies and company, but our main focus as always is to offer stem cell therapies to all patients in need. USRM intends to take full advantage of this RMAT opportunity. We are actively seeking strategic partners to pursue commercialization of the MyoCell™ product and finalize RMAT designation based on the draft guidelines published.

While we are considering partnership opportunities, our current resources are best served focusing on our in-clinic programs that provide treatments to patients every day. Our phones are ringing off the hook with patients interested in pursuing these potentially life-changing therapies.

I will continue the work of expanding regenerative medicine and fighting for patients’ rights to harness their own bodies healing potential. This next year will surely bring many new accomplishments, growth and an expansion of stem cell treatments. All of us here at U.S. Stem Cell, Inc. would like to thank you for your support and wish you a very Happy Holidays and prosperous New Year.

Warmest Regards,

Kristin Comella, PhD, CSO

Read More

Adipocell™ Stem Cell Therapy Shows Safety In A Wide Variety of Applications

Adipocell™ Stem Cell Therapy Shows Safety In A Wide Variety of Applications

Chief Scientific Officer to Present Data at Worldwide Conference

MIAMI, FL –Dec. 1, 2017 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer Dr. Kristin Comella will present at the Healthy Masters Worldwide Forum, Saturday, Dec. 2.

Dr. Comella, who is a global leader in the development of revolutionary holistic stem cell therapies, will discuss progress in the wide use of stem cells from a patient’s own adipose (fat) tissue, which offer a novel therapy for damaged tissue from a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  Her presentation, entitled “Regenerative Medicine: The Future of Medicine is Here,” includes results of a safety study and a knee study — each of which indicate stem cells harvested using USRM’s proprietary Adipocell procedures are safe and effective, respectively, and are a novel therapy for patients with damaged tissue.

Adipocell is a kit of disposables and reagents used to isolate a patient’s own stem cells from fat, which is collected via an outpatient procedure.  Once harvested and isolated, stromal vascular fraction (SVF) is injected into patients which may reduce inflammation, promote healing, and repair damaged/scarred tissue. The SVF population includes mesenchymal stem cells (MSCs), pericytes, endothelial/progenitor cells, fibroblasts and growth factors where the adipocyte (fat cell) population has been removed.

In the safety study, which was published in the Journal of Clinical Medicine Research, an in-clinic use of stromal vascular fraction (SVF) was used for degenerative diseases in orthopedics, neurological conditions and systemic conditions. Approximately 60 ml of fat tissue was removed from each of the 676 patients using a local tumescent liposuction procedure. The fat was processed using the Adipocell™ kit and separated via centrifuge to isolate the SVF, and the cells were delivered intraarticularly, intravenously, intrathecally, or intradiscally directly into each patient. All subjects were monitored for adverse events.

Results of the procedure demonstrated exceptional patient safety, and the study underscores the safety of autologous stem cell therapy in general. Few adverse events were reported and were overwhelmingly of mild and transient nature, such as the expected soreness at the site of liposuction and occasional headache.  Overall, the study demonstrates a strong safety profile with low complication rates.

In the knee study, which was published in the Journal of Translational Medicine, a total of ten patients underwent a local tumescent liposuction procedure to remove approximately 100 ml of fat tissue from each patient.  SVF was isolated using USRM’s proprietary Adipocell enzyme digestion and resuspended in Platelet Rich Plasma (PRP) for intra-articular injection in the knee.

The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score and six-minute walk distance (6MWD) were used to evaluate clinical effects and included measure of patient’s subjective assessment of pain, joint mobility, and physical disability. WOMAC score, 6MWD and laboratory tests were repeated at 3 and 6 months and 1, 1.5 and 2 years. XRAY and MRI were completed at 1 year.

The average total WOMAC score was 64 at baseline and significantly reduced to 52 at 3 months, 46 at 6 months, 42 at 1 year, 38 at 1.5 years, and 41 at 2 years. Patients walked an average of 1310 feet at baseline and demonstrated a statistically significant improvement at 3 and 6 months and 1, 1.5, and 2 years post treatment. Cartilage thickness as determined by MRI improved by at least 0.2 mm in six patients, was unchanged in two patients and decreased by at least 0.2 mm in two patients.

Overall, all of the patients were pleased with the treatment results. They reported a reduction in pain levels, especially after 3 months. More importantly, the procedure demonstrated a strong safety profile with no severe adverse events or complications reported.

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician/veterinary training and certification and stem cell products and protocols.  USRM also provides stem cell banking for patients and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years, and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.

###

About U.S. Stem Cell, Inc.

U.S. Stem Cell, Inc. is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell-based therapies that prevent or treat disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function.Our business, which includes three operating divisions (U.S. Stem Cell Training, Vetbiologics and U.S. Stem Cell Clinic) includes the development of proprietary cell therapy products, as well as revenue generating physician and patient-based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinics. 

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2016, and its Quarterly Reports on Form 10-Q.

Read More